satralizumab news

All news on satralizumab (also known as Enspryng): plants, production capacities, investments and involved companies.

31 July 2026

Chugai files for Enspryng indication to prevent relapses in MOGAD in Japan

Regulatory submission seeks approval of satralizumab to prevent relapse in MOG antibody‑associated disease after Phase III showed a 68% risk reduction.
30 June 2026

Roche’s Enspryng wins FDA Priority Review for at‑home subcutaneous TED treatment

FDA accepted an sBLA and granted Priority Review for the first at‑home subcutaneous option for thyroid eye disease; decision expected 15 Oct 2026.

Who will be producing satralizumab in the future?

Find out with chemXplore Alpha

Learn more